In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva Therapeutics PLC

www.nabriva.com

Latest From Nabriva Therapeutics PLC

Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Coronavirus COVID-19

EU Approvals In Sight For Novartis, Roche, and Janssen

EU approval is a formality for the eight products given the nod this week at the European Medicines Agency. There's no word, though, on filgotimid, from Gilead/Galapagos.

Europe BioPharmaceutical

EU Approval Nod Possible For Novartis, Gilead/Galapagos, and Janssen

The May meeting of the European Medicines Agency’s drug evaluation committee, the CHMP, is under way. Decisions are due on whether eight marketing approval applications should be approved for marketing in the EU.

Europe Drug Review

Antibiotics Could See New Boosts From Medicare Rule, House Bill

US House looks to give BARDA more money for antibiotic development in next coronavirus relief bill, while Medicare broadens the types of antibiotics eligible for additional payments to include drugs approved under FDA's limited population antibiotic development pathway. But it's unclear whether the House funding can make it through the Senate and how meaningful the Medicare provision will be given few LPAD approvals.

Medicare Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Antibiotic Research Institute
  • Nabriva Therapeutics AG
  • 1641640
  • Nabriva Therapeutics Forschungs GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Nabriva Therapeutics PLC
  • Senior Management
  • Ted Schroeder, CEO
    Gary Sender, CFO
    Francesco Maria Lavino, Chief Commercial Officer
    Jennifer Schranz, MD, CMO
    Steven Gelone, MD, Pres. & COO
  • Contact Info
  • Nabriva Therapeutics PLC
    Phone: (43) 1 649 2000
    25-28 North Wall Quay
    Dublin, 1
    Ireland
UsernamePublicRestriction

Register